

HOUSE BILL No. 1129

DIGEST OF INTRODUCED BILL

Citations Affected: IC 16-41-17-2.

Synopsis: Adrenoleukodystrophy (ALD) screening. Requires every infant to be screened for ALD at the earliest feasible time.

Effective: July 1, 2021.

Lauer

January 8, 2020, read first time and referred to Committee on Public Health.



Second Regular Session of the 121st General Assembly (2020)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in **this style type**, and deletions will appear in ~~this style type~~.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in *this style type* or ~~this style type~~ reconciles conflicts between statutes enacted by the 2019 Regular Session of the General Assembly.

HOUSE BILL No. 1129

A BILL FOR AN ACT to amend the Indiana Code concerning health.

Be it enacted by the General Assembly of the State of Indiana:

- 1 SECTION 1. IC 16-41-17-2, AS AMENDED BY P.L.1-2019,
2 SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3 JULY 1, 2021]: Sec. 2. (a) Subject to subsection (d), every infant shall
4 be given examinations at the earliest feasible time for the detection of
5 the following disorders:
6 (1) Phenylketonuria.
7 (2) Hypothyroidism.
8 (3) Hemoglobinopathies, including sickle cell anemia.
9 (4) Galactosemia.
10 (5) Maple Syrup urine disease.
11 (6) Homocystinuria.
12 (7) Inborn errors of metabolism that result in an intellectual
13 disability and that are designated by the state department.
14 (8) Congenital adrenal hyperplasia.
15 (9) Biotinidase deficiency.
16 (10) Disorders detected by tandem mass spectrometry or other
17 technologies with the same or greater detection capabilities as



- 1 tandem mass spectrometry, if the state department determines that
2 the technology is available for use by a designated laboratory
3 under section 7 of this chapter.
- 4 (11) Spinal muscular atrophy.
5 (12) Severe combined immunodeficiency.
6 (13) Beginning July 1, 2020, Krabbe disease.
7 (14) Beginning July 1, 2020, Pompe disease.
8 (15) Beginning July 1, 2020, Hurler syndrome (MPS1).
9 **(16) Adrenoleukodystrophy (ALD).**
- 10 (b) Subject to subsection (d), every infant shall be given a
11 physiologic hearing screening examination at the earliest feasible time
12 for the detection of hearing impairments.
- 13 (c) Beginning January 1, 2012, and subject to subsection (d), every
14 infant shall be given a pulse oximetry screening examination at the
15 earliest feasible time for the detection of low oxygen levels. Section
16 10(a)(2) of this chapter does not apply to this subsection.
- 17 (d) If a parent of an infant objects in writing, for reasons pertaining
18 to religious beliefs only, the infant is exempt from the examinations
19 required by this chapter.

